Experts Caution Against Using GLP-1 as Quick Weight Loss Solution

In New Delhi, a group of leading medical professionals has issued a strong warning about the use of GLP-1 receptor agonists as a quick solution for weight management and diabetes control. These drugs, such as Ozempic, Wegovy, and Mounjaro, are intended for the long-term treatment of chronic conditions like obesity and type 2 diabetes and are not designed for short-term weight loss.

The warning comes following concerns that that the promotion of Semaglutide, a GLP-1 agonist, could lead to shortages among patients who genuinely need it for medical reasons. Dr. Saptarshi Bhattacharya, a Senior Consultant in Endocrinology at Indraprastha Apollo Hospitals, highlighted the recent communication from the Government of India and the Drugs Controller General of India (DCGI), emphasizing that GLP-1 should not be approached as an instant remedy for weight loss and diabetes management.

Dr. Bhattacharya pointed out that while these medications have shown safety and effectiveness, they must be administered under professional medical supervision. He stated that only healthcare providers with an MD in Medicine should prescribe these drugs, as they come with potential side effects that necessitate monitoring by qualified specialists.

Amid these discussions, there has been an intensified effort from regulatory bodies to combat the unauthorized sale of weight-loss drugs. Dr. Monika Sharma, also a Senior Consultant in Endocrinology at Aakash Healthcare, voiced her support for ensuring that GLP-1 drugs are utilized correctly. Improper use of these medications could heighten the risk of severe complications such as gallbladder stones and dehydration, underscoring the need for a proper prescription system to safeguard public health.

Dr. Anil Arora, Chairperson of the Institute of Liver Gastroenterology & Pancreatico Biliary Sciences, remarked on the advantages of GLP-1 medications. He noted, however, that they are only effective during the period of administration. Once usage stops, there is a significant chance—nearly 70%—that individuals will regain lost weight. Initially, when these medications were not available as generics, their costs ranged from Rs 16,000 to Rs 20,000. Following the expiration of the patent, generics have reduced prices to approximately Rs 1,000, making them more accessible.

The challenge of obesity needs continuous medical oversight for effective management. While GLP-1 drugs can contribute to weight loss, their efficacy is maximized when paired with a balanced diet and regular exercise to prevent rebound weight gain. Potential side effects include muscle loss, malnutrition, gastrointestinal complications, pancreatitis, and kidney injury. Thus, it is crucial that these drugs be used strictly following consultation with a healthcare provider.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share